Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Executes the first project for developing and manufacturing a novel anticancer mAb
To accelerate the development of next-generation radioconjugates to treat cancer
Sen spent a decade with Biocon and held various key roles,
Subscribe To Our Newsletter & Stay Updated
